Exelixis & Iconic Therapeutics ink exclusive license and option deal
Category: #health  By Mateen Dalal  Date: 2019-05-18
  • share
  • Twitter
  • Facebook
  • LinkedIn

Exelixis & Iconic Therapeutics ink exclusive license and option deal
  • The exclusive license & option agreement has been signed for a new Antibody-Drug conjugate program.
     
  • The program, named ICON-2, specifically targets Tissue Factor and would have a potential broad impact on oncology.

Exelixis, Inc., (Exelixis), a Californian genomics-based drug discovery firm, has reportedly signed an exclusive license & option agreement with a San Francisco-based clinical-stage biopharmaceutical firm, Iconic Therapeutics (Iconic).

Reports cite, the exclusive license & option agreement has been signed for a new Antibody-Drug conjugate program. The program, named ICON-2, specifically targets Tissue Factor and would have a potential broad impact on oncology.

According to a press release by Exelixis, the collaboration reflects on the company’s current strategy of building a pipeline that goes beyond its own lead product CABOMETYX, through external business development & internal drug discovery both.

The new deal with Iconic is Exelixis’ second strategic partnership that focuses on new biologics, following its collaboration with Invenra, Inc., which was announced in May of 2018. However, the exclusive deal is Iconic’s first strategic partnership in oncology & leverages its expertise in the innovative Tissue-Factor antibody.

Under the terms of the agreement, Exelixis would be gaining exclusive option to license the ICON-2 program in exchange for a $7.5 million upfront payment option to Iconic and a preclinical development funding commitment. Moreover, Exelixis could also exercise its option by making an option exercise payment to take over responsibilities of all subsequent commercialization & clinical development activities at the time of the potential Investigational New Drug (IND) application.

The Executive Vice President & Chief Scientific Officer at Exelixis, Peter Lamb, Ph.D., stated that Iconic is pursuing a highly innovative way to target Tissue Factor, which is a promising target with early clinical validation as well as a potential applicability across an array of different cancers. Dr. Lamb further added that the deal provides Exelixis an attractive entryway to the antibody-drug conjugate domain.

According to reports, the exact amount of the option exercise payment has not been unveiled by any of the involved parties yet.

 

Source Credit:  https://finance.yahoo.com/news/exelixis-iconic-therapeutics-enter-exclusive-120000994.html

http://ir.exelixis.com/news-releases/news-release-details/exelixis-and-iconic-therapeutics-enter-exclusive-option-and

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

MoA Technology targets herbicide resistance crisis & raises $8 million
MoA Technology targets herbicide resistance crisis & raises $8 million
By Mateen Dalal

MoA Technology has created three platforms: MoA SELECTTM, MoA TARGETTM and MoA GALAXYTM, which would work together for effective herbicide creation.   MoA Technology is borne out of Oxford University research is aimed at inhibiting herbicide...

Trump refuses to forge deals with Huawei citing national security
Trump refuses to forge deals with Huawei citing national security
By Mateen Dalal

Donald Trump declares the business with Huawei as a national threat and hence forth has declined all the business opportunities with the company.   The existing contract of the Commerce Department is expected to end sooner. The United Stat...

Trovagene to unveil key study data at APAC Prostate Cancer Conference
Trovagene to unveil key study data at APAC Prostate Cancer Conference
By Mateen Dalal

Data from the Phase 2 Onvansertib clinical trial will be presented at the 20th Prostate Cancer Conference.   The trial assesses the efficacies of Onvansertib on patients with Metastatic Castration-Resistant Prostate Cancer. Trovagene, a cl...